Search Results

Moffitt Cancer Center in the U.S. Launches $600 Million Radiopharmaceutical Program

Moffitt Cancer Center in Tampa, Florida, recently announced the launch of a new radiopharmaceutical program, planning to accelerate radiopharmaceutical research, development, and clinical translation through a total infrastructure investment of $600 million. The program will be advanced at the Speros campus of Moffitt Cancer Center in Pasco County, Florida. The campus spans 775 acres, and the related investment will support the development of radiopharmaceutical research and development capabilities, including the construction of new radiochemistry laboratories within the Moffitt Discovery and Innovation Center, which opens this fall. The innovation center has a building area of approximately 255,000 square feet. The program funding will also support the planned comprehensive theranostics center...

2026-08-27

TEPCO replaces faulty motor of robotic arm at Fukushima Daiichi Unit 2

Tokyo Electric Power Company (TEPCO) began replacing the faulty motor of the robotic arm used for fuel debris retrieval trials at Unit 2 of the Fukushima Daiichi Nuclear Power Station on August 26. The robotic arm, approximately 22 meters long, is planned for use in the third fuel debris retrieval trial. During a previous operational inspection inside the reactor building of Unit 2, TEPCO found that the motor driving the robotic arm had malfunctioned, preventing the brake from releasing and the arm from extending. As the robotic arm is already installed on site, workers will enter the "front chamber" in front of the containment vessel to perform the replacement manually. The company stated that radiation levels in the work area will be strictly controlled to prevent workers from receiving excessive exposure. After this replacement, TEPCO will...

2026-08-27

U.S. Army Plans to Deploy Over 20 Micro Nuclear Reactors at Military Bases

The U.S. Army has signed contracts with five companies to develop, build, and operate micro nuclear power plants at military bases, with a total contract value of up to $2.2 billion. According to relevant information, the U.S. Department of Defense requires the companies to construct, own, and operate more than 20 micro nuclear reactors at military installations by 2028. The plan is intended to enhance energy security for critical defense facilities and reduce dependence on the external power grid. The deployment is incorporated into the framework of the Janus Project, which the U.S. Army launched in 2025. The project aims to establish a power supply network composed of compact micro nuclear reactors at military bases, providing continuous and stable electricity to vital defense facilities....

2026-08-27

Two production lines at radiopharmaceutical plant in Russia's Kaluga Region enter trial production

Rosatom recently announced that two production lines at its modern radiopharmaceutical manufacturing facility in the Kaluga Region have entered trial production. The facility, built in accordance with the Eurasian Economic Union's international Good Manufacturing Practice (GMP) standards, is equipped with high-level production equipment and is designed to supply safe, quality-controlled radiopharmaceuticals to the market. According to reports, Rosatom's subsidiary enterprises currently produce more than ten registered diagnostic and therapeutic radiopharmaceuticals, involving isotopes such as iodine-123, iodine-131, technetium-99m, and samarium-153. The new plant's production plan is based on the demand for radioisotope products from Russian medical institutions through 2030. The company...

2026-08-26

Molecular Partners Advances DLL3 Radiopharmaceutical MP0712 to Higher Dose Cohort

Swiss clinical-stage biotechnology company Molecular Partners AG recently announced its business progress and financial results for the first half of 2026. The company stated that its DLL3-targeting radioactive DARPin therapy MP0712 has advanced to the second therapeutic dose level in a U.S. multicenter Phase 1/2a clinical study, and patient enrollment for the new dose cohort is currently underway. MP0712 is a radiopharmaceutical targeting the tumor-associated antigen DLL3, carrying a therapeutic alpha-emitting radionuclide lead-212 (Pb-212) payload, co-developed by Molecular Partners and Orano Med, primarily for small cell lung cancer and other neuroendocrine tumors. According to the company's disclosure, the first dose cohort of MP0712...

2026-08-26

Russia and Algeria Advance Cooperation in Peaceful Uses of Nuclear Energy

August 22 news, Russian Ambassador to Algeria Alexey Solomatin said in an interview that Russia and Algeria are advancing cooperation in the field of peaceful uses of nuclear energy, with direct working contacts established between the relevant agencies of the two countries. Solomatin stated that cooperation between the two countries in this field is expanding. The basis for bilateral cooperation is the Intergovernmental Agreement on Cooperation in the Peaceful Uses of Nuclear Energy signed in 2014. In addition, Russia and Algeria signed the Roadmap for Cooperation in the Peaceful Uses of Nuclear Energy during the 2024 International Atomic Energy Expo (Atomexpo), outlining the main directions of bilateral cooperation. He noted that the practical implementation of the agreements will begin in 2...

2026-08-25

Atom High-Tech Adds New Radiopharmaceutical Production Base in Changchun

The Jilin Provincial Medical Products Administration issued a public notice on August 21 stating that, in accordance with the Drug Administration Law of the People's Republic of China, the Regulations on the Administration of Radiopharmaceuticals, the Measures for the Supervision and Administration of Drug Production, and other relevant provisions, following on-site inspection and review approval, it intends to issue the Radiopharmaceutical Production License to Changchun Atom High-Tech Pharmaceutical Co., Ltd. The public notice period is 5 working days, subject to public supervision. The notice information shows that the registered address of Changchun Atom High-Tech Pharmaceutical Co., Ltd. is located at No. 770 Shengye Road, Beihu Science and Technology Development Zone, Changchun City, Jilin Province, and the proposed production address for the license is consistent with the registered address. The proposed production scope for this license is small-volume injections for in vivo radiopharmaceuticals, involving products such as Sodium Pertechnetate [99mTc] Injection, Technetium [99mTc] Methylenediphosphonate Injection, Technetium [99mTc] Methoxyisonitrile Injection, Technetium [99mTc] Pentetate Injection, Technetium [99mTc] Ethyl Cysteinate Dimer Injection, and Technetium [99mTc] Etifenin Injection.

2026-08-24

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

South Korea's Asan Medical Center Develops AI-Based Radiopharmaceutical Therapy Platform with U.S. Institutions

The research team at Asan Medical Center in Seoul announced on the 21st that it has recently been selected for the "2026 Korea-U.S. Innovative Outcomes R&D New Support Project" organized by the Ministry of Health and Welfare, and will collaborate with U.S. research institutions to develop an artificial intelligence-based radiopharmaceutical therapy platform aimed at exploring new treatment strategies for solid tumors that respond poorly to conventional therapies. The team is composed of professors including Myung Seung-jae from the Department of Gastroenterology, Oh Seung-jun from the Department of Nuclear Medicine, Ryu Chang-hoon from the Department of Oncology, Jung Byung-kwan from the Department of Pathology, and Son Byung-ho from the Department of Breast Surgery at Asan Medical Center. The project will combine Asan Medical Center's large-scale clinical and pathological data, Emory University's AI-based digital pathology analysis technology, and Case Western Reserve University and University Hospitals Cleveland Medical Center's pathological and clinical research capabilities.

2026-08-22

Armenia to Select Technology Solution for New Nuclear Power Plant by End of 2027

The Armenian government has set the end of 2027 as the deadline for selecting the technology solution for a new nuclear power plant. The project will eventually replace the existing Metsamor Nuclear Power Plant and has been incorporated into Armenia's government program for 2026 to 2031. According to the program, Armenia will advance the construction project for the new nuclear power plant and complete the reactor technology selection by at least the end of 2027. At present, the government has not yet disclosed the installed capacity, reactor type, or potential contractor for the new plant. Armenia has been evaluating nuclear power options from multiple countries in recent years, including both traditional large- or medium-sized nuclear units and small modular reactors (SMRs). Armenian officials have previously stated that units of relatively smaller scale, which are easier to connect to the national grid, are one of the key areas of focus for the government.

2026-08-23

Indiana University Health Establishes Center of Excellence in Theranostics to Advance Precision Targeted Cancer Therapy

Indiana University Health is establishing a new Center of Excellence in Theranostics, planning to provide cancer patients with more personalized diagnostic and treatment services through theranostic technologies. The project combines advanced medical imaging, precision diagnostics, and image-guided targeted therapy, aiming to enhance access to relevant medical services for patients in Indiana. Partial funding comes from a $20 million donor contribution, with Indiana University providing matching funds to bring total donations to $40 million. According to Indiana University, theranostics is a technological approach that integrates diagnosis and treatment. Clinically, advanced imaging techniques are first used...

2026-08-23

Iran Restarts Cyclotron to Boost Supply of Radiopharmaceuticals for Cancer Diagnosis and Treatment

Iranian nuclear industry experts have recently resumed operation of a cyclotron used in nuclear medicine, which can produce radioisotopes needed for cancer diagnosis and treatment. According to plans, by the end of Iran's Seventh Development Plan, i.e., March 2029, Iran will have seven such centers to expand domestic supply capacity for medical radioisotopes. A cyclotron is a type of particle accelerator that can be used to produce nuclear medicine radioisotopes and further prepare radiopharmaceuticals. These drugs can be used for the detection, diagnosis, and monitoring of malignant tumors. Data shows that related products produced domestically in Iran include FDG and F-PSMA, primarily serving nuclear medicine diagnosis and treatment for various cancers...

2026-08-21

Fire alarm triggered for sixth time in August at Japan's Fukushima Daiichi Nuclear Power Station; fire department confirms no fire occurred

At approximately 3:54 a.m. on August 21, a fire alarm was triggered on the first floor of the access control building at the Fukushima Daiichi Nuclear Power Station. Tokyo Electric Power Company (TEPCO) stated that no open flames or smoke were found near the site; shortly after 5:00 a.m., the fire department confirmed that the alarm was not caused by a fire. Readings from radiation monitoring stations around the plant also showed no significant fluctuations. This was the sixth fire alarm at the Fukushima Daiichi Nuclear Power Station since the beginning of August. Previously, the maintenance building for Units 5 and 6 triggered a fire alarm on August 8; the emergency diesel generator room for the high-pressure core spray system of Unit 6 triggered a fire alarm on August 12; the main administration building triggered a fire alarm on August 13...

2026-08-21

Atom High-Tech and CNNC Headway Visit Tsinghua University for Business Cooperation Exchange

On August 17, Luo Xu, General Manager of Atom High-Tech, and Liu Wen, Chairman of CNNC Headway, led a delegation to Tsinghua University for a business cooperation exchange with the School of Biomedical Engineering. Hu Ye, Dean of the School of Biomedical Engineering, and Ma Kai, Associate Professor of the School, attended the exchange. The visit aimed to leverage the research and talent advantages of a top-tier university, promote deep integration of industry, academia, and research, and jointly explore new cooperation opportunities in the fields of nuclear medicine and biomedical engineering. During the exchange meeting, Atom High-Tech and CNNC Headway respectively introduced their corporate development histories, core business layouts, and future strategic plans. Subsequently, Dean Hu Ye and Associate Professor Ma Kai respectively introduced...

2026-08-21

Brazilian CancerThera Delegation Visits Uruguay's CUDIM to Advance Theranostics Cooperation in Oncology

Following the institutional partnership established between CEPID CancerThera and the Uruguayan Center for Molecular Imaging (CUDIM) in February this year, a Brazilian delegation visited Montevideo, Uruguay, from July 27 to 29 to advance the transformation of the memorandum of understanding into a concrete work plan. The visit focused on multicenter clinical trials, preclinical research, theranostics in oncology, and educational cooperation. During the visit, Brazilian researchers held working meetings with the CUDIM team, covering multiple aspects of oncology research development. CUDIM was represented by its General Director Alarico Rodriguez, as well as radiopharmacist and Technical Director of Radiopharmacy, Dr. Eduardo Osvaldo Savio Queve...

2026-08-20